article thumbnail

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

Philadelphia, PA PCI Pharma Services (“PCI”), a leading global contract development and manufacturing organization (CDMO) specializing in complex biopharma therapies, has announced a monumental investment exceeding $365 million. Operations at the first phase of the plant are scheduled to begin in Q3 2025.

article thumbnail

AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01

The Pharma Data

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia. Source link.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

BioTech 365

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 Response to pre-IND briefing package supports pathway to initiating a Phase 1 … Continue reading →

article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues. Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments.

RNA 147
article thumbnail

FDA INTERACT Meetings: Early Interactions for Cell and Gene Therapy Sponsors

Camargo

A 2020 PhRMA report on the cell and gene therapy pipeline found 362 therapies in a range of stages in clinical development by biopharmaceutical companies in the United States. Source: Medicines in Development | 2020 Update: Cell and Gene Therapy , PhRMA. Note: Some medicines are in more than one category.

article thumbnail

Regulatory Strategy Considerations for Working with the FDA vs the EMA, Part 1

Camargo

Meeting Package Due. To address a stalled product development plan or an important safety issue. Sponsors whose products qualify for the centralized procedure can also seek scientific advice from the EMA anytime during development. All four types are free of charge to the sponsor, in contrast to EU meetings (discussed below).

article thumbnail

Diversity Action Plans (DAPs) in Clinical Trials Are No Longer a “Nice-to-Have” — Are You Ready?

XTalks

They shared their extensive knowledge of the importance and implementation of diversity action plans in clinical trials. Dr. Oblak brings over a decade of experience in drug development, focusing on global clinical development programs and the development of Diversity Action Plans.